CStone Pharmaceuticals Seeks EMA Approval for Sugemalimab in Stage III NSCLC

CStone Pharmaceuticals has taken a significant step toward expanding the global reach of sugemalimab, submitting a Type II variation application to the European Medicines Agency (EMA) for unresectable stage III non-small cell lung cancer (NSCLC). If approved, sugemalimab would become only the second PD-L1 inhibitor available in Europe for this indication, reinforcing its potential as a cornerstone immunotherapy. This follows its 2024 EMA approval for metastatic NSCLC, highlighting CStone’s ongoing commitment to addressing unmet needs in lung cancer treatment.

The GEMSTONE-301 Phase III trial underpins the submission, showcasing a 36% reduction in disease progression risk and a 56% decrease in the risk of death. The trial also confirmed a strong overall survival trend and a favorable safety profile. Dr. Jason Yang, CEO of CStone, emphasized the company’s dedication to broadening global access through regulatory collaborations, stating: "With its demonstrated efficacy and safety, sugemalimab is well-positioned to transform treatment outcomes for stage III NSCLC patients."